Brown Brothers Harriman & Co. decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 529,494 shares of the medical research company's stock after selling 10,874 shares during the quarter. Thermo Fisher Scientific accounts for about 1.9% of Brown Brothers Harriman & Co.'s holdings, making the stock its 19th biggest holding. Brown Brothers Harriman & Co. owned about 0.14% of Thermo Fisher Scientific worth $275,459,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Geode Capital Management LLC boosted its stake in Thermo Fisher Scientific by 1.7% in the third quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock valued at $4,719,477,000 after acquiring an additional 127,564 shares in the last quarter. Coldstream Capital Management Inc. boosted its position in shares of Thermo Fisher Scientific by 11.4% in the 3rd quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock valued at $5,972,000 after purchasing an additional 995 shares during the period. Greenwood Gearhart Inc. increased its position in Thermo Fisher Scientific by 9.8% during the third quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock worth $12,730,000 after buying an additional 1,837 shares during the period. Nordea Investment Management AB lifted its stake in Thermo Fisher Scientific by 23.6% in the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock valued at $28,868,000 after buying an additional 10,606 shares during the last quarter. Finally, S.E.E.D. Planning Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 6.2% in the fourth quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock valued at $5,528,000 after acquiring an additional 618 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts recently commented on TMO shares. Bank of America reduced their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating for the company in a research report on Friday, December 13th. Citigroup decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. UBS Group upped their price objective on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Scotiabank boosted their target price on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a report on Monday, February 3rd. Finally, Royal Bank of Canada set a $693.00 price target on Thermo Fisher Scientific in a report on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $653.23.
Read Our Latest Stock Report on Thermo Fisher Scientific
Insider Transactions at Thermo Fisher Scientific
In related news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock valued at $13,106,062 over the last three months. 0.34% of the stock is currently owned by insiders.
Thermo Fisher Scientific Price Performance
TMO traded down $15.09 during trading on Tuesday, reaching $482.51. 1,826,854 shares of the stock were exchanged, compared to its average volume of 1,620,448. Thermo Fisher Scientific Inc. has a 1 year low of $481.47 and a 1 year high of $627.88. The company has a market capitalization of $182.03 billion, a price-to-earnings ratio of 29.19, a P/E/G ratio of 2.99 and a beta of 0.79. The business's 50 day moving average price is $540.37 and its two-hundred day moving average price is $551.02. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.
Thermo Fisher Scientific Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.36%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.41%.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
